Tumour necrosis factor: Strategies for improving the therapeutic index

A. Corti, F. Marcucci

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Tumour Necrosis Factor (TNF) is a cytokine initially discovered for its capacity to induce haemorragic necrosis of experimental tumours and later found to be endowed with potent proinflammatory activities. It was soon realised that these latter properties were at the origin of unacceptable systemic toxicity in all trials aimed at exploiting the anti-tumour activities of TNF. The present review intends to reconsider the efforts that have been devoted over the past ten years to increase the therapeutic index of TNF so to make it a useful drug for the treatment of malignancies. Overall, attempts to achieve this goal with systemically administered TNF have met little success so far. On the other hand, impressive results have been obtained with locoregional administration of TNF. Although of relatively limited clinical utility, these observations have indicated a realistic possibility for a therapeutic exploitation of TNF in tumour therapy: the delivery of systemically administered TNF to the site of tumour growth. On this basis, different targeting and pre-targeting strategies have been developed to achieve this goal. While still in their infancy, these approaches have yielded encouraging results in experimental tumour models. In the forthcoming years it will be possible to evaluate if they represent a practicable means of delivering high doses of TNF to the tumour while sparing the organism from systemic, toxic effects.

Original languageEnglish
Pages (from-to)403-413
Number of pages11
JournalJournal of Drug Targeting
Volume5
Issue number6
Publication statusPublished - 1998

Fingerprint

Tumor Necrosis Factor-alpha
Neoplasms
Therapeutics
Poisons
Theoretical Models
Necrosis
Cytokines
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Tumour necrosis factor : Strategies for improving the therapeutic index. / Corti, A.; Marcucci, F.

In: Journal of Drug Targeting, Vol. 5, No. 6, 1998, p. 403-413.

Research output: Contribution to journalArticle

@article{6d00e5bed78d489f98704bcd1f171483,
title = "Tumour necrosis factor: Strategies for improving the therapeutic index",
abstract = "Tumour Necrosis Factor (TNF) is a cytokine initially discovered for its capacity to induce haemorragic necrosis of experimental tumours and later found to be endowed with potent proinflammatory activities. It was soon realised that these latter properties were at the origin of unacceptable systemic toxicity in all trials aimed at exploiting the anti-tumour activities of TNF. The present review intends to reconsider the efforts that have been devoted over the past ten years to increase the therapeutic index of TNF so to make it a useful drug for the treatment of malignancies. Overall, attempts to achieve this goal with systemically administered TNF have met little success so far. On the other hand, impressive results have been obtained with locoregional administration of TNF. Although of relatively limited clinical utility, these observations have indicated a realistic possibility for a therapeutic exploitation of TNF in tumour therapy: the delivery of systemically administered TNF to the site of tumour growth. On this basis, different targeting and pre-targeting strategies have been developed to achieve this goal. While still in their infancy, these approaches have yielded encouraging results in experimental tumour models. In the forthcoming years it will be possible to evaluate if they represent a practicable means of delivering high doses of TNF to the tumour while sparing the organism from systemic, toxic effects.",
author = "A. Corti and F. Marcucci",
year = "1998",
language = "English",
volume = "5",
pages = "403--413",
journal = "Journal of Drug Targeting",
issn = "1061-186X",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Tumour necrosis factor

T2 - Strategies for improving the therapeutic index

AU - Corti, A.

AU - Marcucci, F.

PY - 1998

Y1 - 1998

N2 - Tumour Necrosis Factor (TNF) is a cytokine initially discovered for its capacity to induce haemorragic necrosis of experimental tumours and later found to be endowed with potent proinflammatory activities. It was soon realised that these latter properties were at the origin of unacceptable systemic toxicity in all trials aimed at exploiting the anti-tumour activities of TNF. The present review intends to reconsider the efforts that have been devoted over the past ten years to increase the therapeutic index of TNF so to make it a useful drug for the treatment of malignancies. Overall, attempts to achieve this goal with systemically administered TNF have met little success so far. On the other hand, impressive results have been obtained with locoregional administration of TNF. Although of relatively limited clinical utility, these observations have indicated a realistic possibility for a therapeutic exploitation of TNF in tumour therapy: the delivery of systemically administered TNF to the site of tumour growth. On this basis, different targeting and pre-targeting strategies have been developed to achieve this goal. While still in their infancy, these approaches have yielded encouraging results in experimental tumour models. In the forthcoming years it will be possible to evaluate if they represent a practicable means of delivering high doses of TNF to the tumour while sparing the organism from systemic, toxic effects.

AB - Tumour Necrosis Factor (TNF) is a cytokine initially discovered for its capacity to induce haemorragic necrosis of experimental tumours and later found to be endowed with potent proinflammatory activities. It was soon realised that these latter properties were at the origin of unacceptable systemic toxicity in all trials aimed at exploiting the anti-tumour activities of TNF. The present review intends to reconsider the efforts that have been devoted over the past ten years to increase the therapeutic index of TNF so to make it a useful drug for the treatment of malignancies. Overall, attempts to achieve this goal with systemically administered TNF have met little success so far. On the other hand, impressive results have been obtained with locoregional administration of TNF. Although of relatively limited clinical utility, these observations have indicated a realistic possibility for a therapeutic exploitation of TNF in tumour therapy: the delivery of systemically administered TNF to the site of tumour growth. On this basis, different targeting and pre-targeting strategies have been developed to achieve this goal. While still in their infancy, these approaches have yielded encouraging results in experimental tumour models. In the forthcoming years it will be possible to evaluate if they represent a practicable means of delivering high doses of TNF to the tumour while sparing the organism from systemic, toxic effects.

UR - http://www.scopus.com/inward/record.url?scp=0031740227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031740227&partnerID=8YFLogxK

M3 - Article

C2 - 9783674

AN - SCOPUS:0031740227

VL - 5

SP - 403

EP - 413

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1061-186X

IS - 6

ER -